CY1110813T1 - Χημικες ενωσεις - Google Patents
Χημικες ενωσειςInfo
- Publication number
- CY1110813T1 CY1110813T1 CY20101100879T CY101100879T CY1110813T1 CY 1110813 T1 CY1110813 T1 CY 1110813T1 CY 20101100879 T CY20101100879 T CY 20101100879T CY 101100879 T CY101100879 T CY 101100879T CY 1110813 T1 CY1110813 T1 CY 1110813T1
- Authority
- CY
- Cyprus
- Prior art keywords
- chemical compounds
- compounds
- 11βhsd1
- inhibition
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86430306P | 2006-11-03 | 2006-11-03 | |
| US86424706P | 2006-11-03 | 2006-11-03 | |
| EP07824375A EP2086939B8 (en) | 2006-11-03 | 2007-10-31 | Pyridine carboxamides as 11-beta-hsd1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110813T1 true CY1110813T1 (el) | 2015-06-10 |
Family
ID=39304797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100879T CY1110813T1 (el) | 2006-11-03 | 2010-10-04 | Χημικες ενωσεις |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7964618B2 (OSRAM) |
| EP (2) | EP2086939B8 (OSRAM) |
| JP (1) | JP5165688B2 (OSRAM) |
| KR (1) | KR101465275B1 (OSRAM) |
| CN (3) | CN101573336B (OSRAM) |
| AR (1) | AR063458A1 (OSRAM) |
| AT (1) | ATE475649T1 (OSRAM) |
| AU (1) | AU2007315955B2 (OSRAM) |
| BR (1) | BRPI0717970C1 (OSRAM) |
| CA (1) | CA2668006C (OSRAM) |
| CL (1) | CL2007003176A1 (OSRAM) |
| CO (1) | CO6321130A2 (OSRAM) |
| CY (1) | CY1110813T1 (OSRAM) |
| DE (1) | DE602007008137D1 (OSRAM) |
| DK (1) | DK2086939T3 (OSRAM) |
| ES (2) | ES2347491T3 (OSRAM) |
| HR (1) | HRP20100522T1 (OSRAM) |
| IL (1) | IL198231A0 (OSRAM) |
| MX (1) | MX2009004707A (OSRAM) |
| NO (1) | NO20091603L (OSRAM) |
| NZ (1) | NZ576501A (OSRAM) |
| PE (1) | PE20081487A1 (OSRAM) |
| PL (1) | PL2086939T3 (OSRAM) |
| PT (1) | PT2086939E (OSRAM) |
| RS (1) | RS51451B (OSRAM) |
| RU (1) | RU2451674C2 (OSRAM) |
| SI (1) | SI2086939T1 (OSRAM) |
| TW (1) | TW200827346A (OSRAM) |
| UY (1) | UY30681A1 (OSRAM) |
| WO (1) | WO2008053194A2 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1953145B1 (en) | 2005-11-21 | 2015-11-04 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i |
| TW200827346A (en) * | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| TW200836719A (en) * | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| BRPI0811191A2 (pt) | 2007-05-18 | 2014-10-29 | Shionogi & Co | Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2202228B1 (en) * | 2007-10-15 | 2014-12-10 | Takeda Pharmaceutical Company Limited | Amide compounds and use of the same |
| WO2009056881A1 (en) * | 2007-10-29 | 2009-05-07 | Astrazeneca Ab | Chemical compounds 313 |
| US7951833B2 (en) * | 2008-02-04 | 2011-05-31 | Astrazeneca Ab | Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471 |
| WO2009130496A1 (en) * | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
| US8507493B2 (en) | 2009-04-20 | 2013-08-13 | Abbvie Inc. | Amide and amidine derivatives and uses thereof |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| US20110092526A1 (en) * | 2009-10-20 | 2011-04-21 | Astrazeneca Ab | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 |
| JP2013512243A (ja) * | 2009-11-24 | 2013-04-11 | アラーガン インコーポレイテッド | 治療的有用性を有する受容体調節物質としての新規化合物 |
| WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US9464078B2 (en) | 2010-09-23 | 2016-10-11 | Abbvie Inc. | Monohydrate of azaadamantane derivatives |
| US8471027B2 (en) * | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
| WO2013010382A1 (zh) * | 2011-07-21 | 2013-01-24 | 山东亨利医药科技有限责任公司 | 杂环取代的嘧啶类化合物 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102659657B (zh) * | 2012-04-24 | 2014-08-06 | 徐州医学院 | 一种蛋白酶抑制剂pf429242的合成方法 |
| EA201492285A1 (ru) | 2012-06-20 | 2015-04-30 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) |
| HK1206341A1 (en) | 2012-06-20 | 2016-01-08 | 霍夫曼-拉罗奇有限公司 | Substituted pyrazole compounds as lpar antagonists |
| EP3821892A1 (en) | 2019-11-12 | 2021-05-19 | University of Leeds | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds |
| GB202216324D0 (en) * | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
| GB202408335D0 (en) | 2024-06-11 | 2024-07-24 | Astrazeneca Ab | Therapies for wound treatment |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR66581B (OSRAM) * | 1978-02-21 | 1981-03-27 | Delalande Sa | |
| US4734418A (en) | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| CN102584799A (zh) | 1999-09-16 | 2012-07-18 | 田边三菱制药株式会社 | 含氮的6-员芳香环化合物 |
| FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
| US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| CA2426430C (en) | 2000-10-20 | 2014-10-07 | Biocryst Pharmaceuticals, Inc. | Biaryl compounds as serine protease inhibitors |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| WO2003086410A1 (en) | 2002-04-05 | 2003-10-23 | The University Of Edinburgh | Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
| WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| DE602004027171D1 (de) | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| CN1832741A (zh) | 2003-08-07 | 2006-09-13 | 默克公司 | 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类 |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| JP2007514731A (ja) | 2003-12-19 | 2007-06-07 | ファイザー インコーポレイテッド | 糖尿病及び肥満症の治療のための１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型（１１−β−ｈｓｄ−１）の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−２−イル誘導体及び関連化合物 |
| ES2313304T3 (es) | 2004-02-24 | 2009-03-01 | Glaxo Group Limited | Derivados de piridina y su uso como moduladores del receptor cb2. |
| CN1972914A (zh) * | 2004-03-31 | 2007-05-30 | 詹森药业有限公司 | 作为组胺h3受体配合体的非咪唑杂环化合物 |
| JP2007536369A (ja) | 2004-05-06 | 2007-12-13 | ファイザー・インク | プロリン及びモルホリン誘導体の新規化合物 |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| PT1763517E (pt) | 2004-06-28 | 2011-07-01 | Hoffmann La Roche | Derivados de pirimidina como inibidores 11beta-hsd1 |
| EP1812407A2 (en) | 2004-11-02 | 2007-08-01 | Pfizer, Inc. | Novel compounds of substituted and unsubstituted adamantyl amides |
| JP2008519034A (ja) | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
| CA2594098C (en) | 2005-01-05 | 2014-04-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| BRPI0610459A2 (pt) * | 2005-04-05 | 2010-06-22 | Hoffmann La Roche | composto, processo para a sua preparação, composições farmacêuticas que o compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróides-11b e utilização do composto |
| RU2404164C2 (ru) | 2005-04-06 | 2010-11-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридин-3-карбоксамида в качестве обратных агонистов св1 |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| EP2527337A1 (en) * | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| EP1891069A1 (en) | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| US8952176B2 (en) | 2005-06-07 | 2015-02-10 | Shionogi & Co., Ltd. | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity |
| CA2610172A1 (en) | 2005-06-08 | 2006-12-14 | Japan Tobacco Inc. | Heterocyclic compound |
| DE602006010546D1 (de) | 2005-06-16 | 2009-12-31 | Pfizer | N-(pyridin-2-yl)sulfonamidderivate |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| JP2009504621A (ja) | 2005-08-09 | 2009-02-05 | アストラゼネカ アクチボラグ | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 |
| CN101316837A (zh) | 2005-11-01 | 2008-12-03 | 詹森药业有限公司 | 作为葡萄糖激酶变构调节剂的取代的吡咯酮类 |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| EP1953145B1 (en) | 2005-11-21 | 2015-11-04 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i |
| TW200804341A (en) | 2006-01-31 | 2008-01-16 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| ES2548002T3 (es) | 2006-03-22 | 2015-10-13 | F. Hoffmann-La Roche Ag | Pirazoles como 11beta-SD1 |
| WO2007115935A1 (en) | 2006-04-07 | 2007-10-18 | High Point Pharmaceuticals, Llc | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| CA2650567A1 (en) | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Use of cbx cannabinoid receptor modulators as potassium channel modulators |
| US20100022589A1 (en) * | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| TW200827346A (en) * | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| BRPI0811191A2 (pt) | 2007-05-18 | 2014-10-29 | Shionogi & Co | Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1 |
| CN101743226B (zh) | 2007-07-17 | 2012-10-10 | 霍夫曼-拉罗奇有限公司 | 11β-羟基类固醇脱氢酶抑制剂 |
| EA201000701A1 (ru) | 2007-11-06 | 2010-12-30 | Астразенека Аб | 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465 |
| US7951833B2 (en) | 2008-02-04 | 2011-05-31 | Astrazeneca Ab | Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471 |
| WO2009130496A1 (en) * | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
| JP2012516327A (ja) | 2009-01-30 | 2012-07-19 | アストラゼネカ アクチボラグ | カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法 |
| US20110092526A1 (en) | 2009-10-20 | 2011-04-21 | Astrazeneca Ab | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 |
-
2007
- 2007-10-29 TW TW096140633A patent/TW200827346A/zh unknown
- 2007-10-30 US US11/928,744 patent/US7964618B2/en active Active
- 2007-10-31 WO PCT/GB2007/004131 patent/WO2008053194A2/en not_active Ceased
- 2007-10-31 DE DE602007008137T patent/DE602007008137D1/de active Active
- 2007-10-31 ES ES07824375T patent/ES2347491T3/es active Active
- 2007-10-31 PL PL07824375T patent/PL2086939T3/pl unknown
- 2007-10-31 AU AU2007315955A patent/AU2007315955B2/en active Active
- 2007-10-31 PT PT07824375T patent/PT2086939E/pt unknown
- 2007-10-31 DK DK07824375.5T patent/DK2086939T3/da active
- 2007-10-31 CA CA2668006A patent/CA2668006C/en active Active
- 2007-10-31 EP EP07824375A patent/EP2086939B8/en active Active
- 2007-10-31 CN CN2007800491675A patent/CN101573336B/zh not_active Expired - Fee Related
- 2007-10-31 EP EP10163730.4A patent/EP2233480B1/en active Active
- 2007-10-31 RU RU2009115830/04A patent/RU2451674C2/ru active
- 2007-10-31 BR BRPI0717970A patent/BRPI0717970C1/pt active IP Right Grant
- 2007-10-31 MX MX2009004707A patent/MX2009004707A/es active IP Right Grant
- 2007-10-31 JP JP2009535119A patent/JP5165688B2/ja active Active
- 2007-10-31 UY UY30681A patent/UY30681A1/es not_active Application Discontinuation
- 2007-10-31 RS RSP-2010/0422A patent/RS51451B/sr unknown
- 2007-10-31 HR HR20100522T patent/HRP20100522T1/hr unknown
- 2007-10-31 KR KR1020097010339A patent/KR101465275B1/ko active Active
- 2007-10-31 AT AT07824375T patent/ATE475649T1/de active
- 2007-10-31 ES ES10163730T patent/ES2423206T3/es active Active
- 2007-10-31 CN CN2012100119350A patent/CN102603711A/zh active Pending
- 2007-10-31 CN CN2010101438299A patent/CN101787016B/zh active Active
- 2007-10-31 SI SI200730335T patent/SI2086939T1/sl unknown
- 2007-10-31 NZ NZ576501A patent/NZ576501A/en not_active IP Right Cessation
- 2007-11-02 AR ARP070104887A patent/AR063458A1/es not_active Application Discontinuation
- 2007-11-02 CL CL200703176A patent/CL2007003176A1/es unknown
- 2007-11-05 PE PE2007001517A patent/PE20081487A1/es not_active Application Discontinuation
-
2009
- 2009-04-20 IL IL198231A patent/IL198231A0/en unknown
- 2009-04-22 NO NO20091603A patent/NO20091603L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043382A patent/CO6321130A2/es not_active Application Discontinuation
- 2009-08-14 US US12/541,565 patent/US8673938B2/en active Active
- 2009-08-14 US US12/541,574 patent/US20090312372A1/en not_active Abandoned
-
2010
- 2010-10-04 CY CY20101100879T patent/CY1110813T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110813T1 (el) | Χημικες ενωσεις | |
| NO20073790L (no) | Kjemiske forbindelser | |
| NO20073788L (no) | Kjemiske forbindelser | |
| SE0301700D0 (sv) | Novel compounds | |
| EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| TW200800999A (en) | Novel compounds | |
| SE0302811D0 (sv) | Novel compounds | |
| UY30759A1 (es) | Compuestos quimicos | |
| TW200716606A (en) | Chemical compounds | |
| TW200800963A (en) | Chemical compounds | |
| UY31145A1 (es) | Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene | |
| TW200801003A (en) | Novel compounds | |
| TW200745084A (en) | Novel compounds | |
| BRPI0815920A2 (pt) | Composto, composição farmacêutica, e, uso do composto. | |
| MY153915A (en) | Organic compounds | |
| UA103319C2 (en) | Thiazole- and oxazole-benzene sulfonamide compounds | |
| CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
| SE0401762D0 (sv) | Novel compounds | |
| UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
| CY1112960T1 (el) | Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων | |
| TW200738627A (en) | Trialkylsilyl-indoles | |
| CY1116000T1 (el) | Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση | |
| TW200738659A (en) | Novel compounds | |
| SE0303541D0 (sv) | New compounds | |
| SE0303280D0 (sv) | Novel compounds |